Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651238 | 1.00 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL653595 | 0.98 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL653597 | 0.98 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2322851 | 0.83 | CHRNB4 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL15492575 | 0.81 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL650890 | 0.80 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL650891 | 0.80 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21851718 | 0.80 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL652204 | 0.79 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL652205 | 0.79 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298775-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | claimed |
| EP-2295437-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-16 | — | — | EP | claimed |
| CN-101935322-A | Diazabicyclic central nervous system active agents | ABBOTT LAB | 2011-01-05 | — | — | CN | claimed |
| CN-101357915-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2009-02-04 | — | — | CN | claimed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | claimed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | claimed |
| CN-1440410-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2003-09-03 | — | — | CN | claimed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | claimed |
| US-8252862-B2 | Silane coupling agents for filled rubbers | BASF SE (DE) | 2012-08-28 | — | — | US | disclosed |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119635-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119710-B2 | Filled rubber compounds with improved processability | BASF SE (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2190912-B1 | SILANE COUPLING AGENTS FOR FILLED RUBBERS | BASF SE (DE) | 2011-11-23 | — | — | EP | disclosed |
| CN-101357915-B | Diazabicyclic central nervous system active agents | ABBOTT LAB | 2011-07-06 | — | — | CN | disclosed |
| US-5814692-A | PROTECTING POLYMERS AND LUBRICANTS AGAINST THERMAL, OXIDATIVE OR LIGHT-INDUCED DEGRADATION | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-09-29 | — | — | US | disclosed |
| US-5773631-A | PROTECTION OF POLYMERS AND LUBRICANTS AGAINST THERMAL, OXIDATIVE OR LIGHT INDUCED DEGRDATION | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-06-30 | — | — | US | disclosed |
| US-5607624-A | Process for the preparation of 3-arylbenzofuranones | CIBA-GEIGY CORPORATION (US) | 1997-03-04 | — | — | US | disclosed |
| US-5516920-A | POLYMER STABILIZERS | CIBA-GEIGY CORPORATION (US) | 1996-05-14 | — | — | US | disclosed |
| US-5356966-A | Stabilizing organic material against oxidative, thermal or light iinduced degradation | CIBA-GEIGY CORPORATION (US) | 1994-10-18 | — | — | US | disclosed |
| US-5252643-A | Heat, oxidation and light stabilizers | CIBA-GEIGY CORPORATION (US) | 1993-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | CHRNB2 10/4885CHRNA4 11/4885CHRNB4 15/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNB4 15/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNB4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.